Therefore, we sought to investigate methods that may improve treatment outcomes for high-risk medulloblastoma patients by preclinically evaluating the radiosensitizing potential of PARP inhibition in MYC-amplified Group 3 medulloblastoma models. Here, MYC is linked to medulloblastoma.